Novo Nordisk’s daily oral semaglutide is a prescription tablet available in 3 mg, 7 mg and 14 mg strengths. In Singapore, it is registered for treating adults with insufficiently controlled type 2 diabetes. It can also reduce appetite and body weight, although prescribing this formulation solely for weight loss is outside its registered indication, known as off-label use.
If you prefer tablets to injections, the practical question is whether this treatment suits your health needs and daily routine. At Edwin Lim Medical Aesthetic Clinic, we start with an in-person consultation to understand your goals and previous treatment. We explain the expected benefits, how to take the tablet correctly and how it compares with treatments registered for weight management.
Oral semaglutide is a once-daily prescription tablet belonging to a group of medicines called GLP-1 receptor agonists. It acts on the same receptors as GLP-1, a naturally occurring hormone involved in appetite and blood sugar regulation.
For weight management, an important part of its action is how it influences the brain’s signals for hunger and fullness. This can reduce the desire to eat and make a smaller meal feel more satisfying. It also slows the early movement of food out of the stomach, although its effect on appetite involves more than digestion alone.
Semaglutide also helps the pancreas release insulin when blood sugar is raised and reduces the release of glucagon, a hormone that signals the liver to release glucose. These actions explain its role in treating type 2 diabetes.
The tablet contains an ingredient that helps semaglutide pass through the stomach lining into the bloodstream. Food, drinks and other tablets can affect this process, which is why following the instructions about water and waiting before breakfast is an important part of treatment.
Yes, oral semaglutide can help some people lose weight by making it easier to eat less. In everyday life, you may notice that hunger feels less strong, a smaller portion leaves you satisfied, or the urge to snack between meals becomes less frequent. These changes can help you reduce your overall calorie intake over time.
For example, you might feel comfortably satisfied with a smaller lunch instead of wanting a second helping. The experience varies, however, and treatment should still allow you to eat regular, nourishing meals. Feeling persistently nauseated or struggling to eat and drink is something to discuss with us, rather than an effect to aim for.
For the 3 mg, 7 mg and 14 mg tablets covered here, the main clinical-trial evidence comes from adults with type 2 diabetes. The amount of weight lost varies with the dose and the individual; the following section explains the study findings in more detail.
If you do not have diabetes, we discuss whether this tablet is appropriate for your circumstances or whether a treatment registered for weight management would better suit your needs. You do not need to arrive knowing which medicine to request. We can work through the options together.
In the PIONEER studies below, people taking oral semaglutide lost an average of a few kilograms over 26 weeks, or approximately six months. These studies involved adults with type 2 diabetes, and the table shows the tablet dose and placebo result so you can see the findings in context.
|
Study and Participants |
Daily Tablet Dose |
Average Weight Change at 26 Weeks |
|---|---|---|
|
PIONEER 1: adults with type 2 diabetes inadequately controlled with diet and exercise |
7 mg |
2.3 kg reduction; placebo group: 1.4 kg reduction |
|
PIONEER 1: same study population |
14 mg |
3.7 kg reduction; placebo group: 1.4 kg reduction |
|
PIONEER 4: adults with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor |
14 mg |
4.4 kg reduction; placebo group: 0.5 kg reduction |
Study note: These analyses included participants who stopped treatment or needed additional diabetes treatment. The studies involved different populations and background medicines, so they are not a direct comparison. In PIONEER 1, the difference from placebo was not statistically significant at 7 mg; it was significant at 14 mg.
Your progress may differ from these averages. At review, we consider your weight trend alongside appetite, side effects and blood sugar where relevant. This helps us judge whether treatment is providing a worthwhile benefit for you, rather than expecting you to match a study result.
You may have read that semaglutide can produce around 15% weight loss. Some of these reports concern weekly injections; others concern oral obesity trials using substantially higher doses, such as 50 mg daily. They do not describe the expected effect of the 3 mg, 7 mg or 14 mg tablets discussed here.
When comparing treatments, we use the evidence for the actual formulation and dose being considered.
For someone with type 2 diabetes, better blood sugar control is an important treatment goal even if weight changes are modest. We consider HbA1c, a blood test reflecting average blood sugar over roughly two to three months, alongside weight and the rest of your diabetes treatment.
The SOUL trial also studied oral semaglutide, up to 14 mg daily, in adults aged 50 or older with type 2 diabetes and established cardiovascular disease, chronic kidney disease or both. Major cardiovascular events occurred in 12.0% of the semaglutide group and 13.8% of the placebo group over an average follow-up of approximately four years. Both groups received standard care.
These findings may be relevant if you have diabetes and existing cardiovascular or kidney disease. They do not show that someone without diabetes would receive the same heart-related benefit when taking the tablet solely for weight loss.
The assessment starts with your medical history and the reason for considering treatment. We review BMI, blood pressure, current medicines and previous attempts to manage weight. If you have diabetes, your existing care and recent blood test results also help guide the discussion.
If injections make you uneasy, please tell us. A daily tablet may feel more manageable, although it needs a routine that allows time before breakfast, drinks or other oral medicines. If you work shifts, eat immediately after waking or take several morning medicines, we can discuss how these fit together before deciding on treatment.
BMI helps us understand weight-related health risks, but it does not determine suitability on its own. The BMI thresholds used for weight-management injections are not the registered prescribing criteria for this diabetes tablet. We consider your health as a whole when discussing the options.
Please tell your doctor about previous pancreatitis, gallbladder problems, severe digestive symptoms or delayed stomach emptying, kidney disease, diabetes-related eye disease, and any personal or family history of thyroid cancer. Having one of these conditions does not automatically rule out treatment, but it may change which medicine we recommend or how closely we monitor you.
Oral semaglutide is not a treatment for type 1 diabetes or a replacement for insulin. Pregnancy and breastfeeding also change the treatment options. Discuss pregnancy plans early: semaglutide should be stopped at least two months before a planned pregnancy and should not be used during pregnancy or breastfeeding.
Treatment begins at a low dose to allow the body time to adjust. The table shows the usual registered schedule. Before increasing the dose, we review how you are responding and whether you are experiencing side effects.
|
Tablet Strength |
Usual Place in the Dosing Schedule |
|---|---|
|
3 mg once daily |
Starting dose for one month |
|
7 mg once daily |
Next dose after the first month |
|
14 mg once daily |
May be considered after at least one month on 7 mg if further blood sugar control is needed |
If nausea or other symptoms are making treatment difficult, contact the clinic before a planned increase. Do not increase the dose yourself or combine tablets to try to achieve a higher dose. The Singapore product information does not recommend taking two 7 mg tablets as a substitute for one 14 mg tablet.
If you have stopped for a prolonged period or are switching from another treatment, let us know what you last took and when. Restarting or switching needs a prescribing plan suited to your circumstances.
The first month on 3 mg is the starting stage of treatment. It gives you time to become familiar with the daily routine and see how well you tolerate the medicine. There is no fixed amount of weight you should expect to lose during this period, and an early reading on the scale does not tell us everything about your response.
Notice whether your appetite changes, whether you can eat and drink comfortably, and whether nausea or other digestive symptoms affect your day. Bring these observations to your review, together with any weight records. If side effects are making treatment difficult, contact the clinic before a planned dose increase so we can advise you on the next step.
Take the tablet on an empty stomach with plain water, using no more than 120 mL. Swallow it whole without splitting, crushing or chewing. Then wait at least 30 minutes before eating, drinking anything further or taking another oral medicine.
A morning routine can make this easier to remember. For example, if you take the tablet at 7.00 am before breakfast, wait until at least 7.30 am before having food, coffee, tea or other tablets. If another medicine also has fasting instructions, ask your doctor or pharmacist to help arrange the timing.
Food, larger amounts of water and other tablets taken at the same time can interfere with absorption. The waiting period helps the medicine work as intended. If you are finding the routine difficult, tell us; reviewing how the tablet is taken can be useful before deciding that the dose needs changing.
Skip the missed dose and take your next dose the following day as prescribed. Do not double the dose to catch up. If you repeatedly miss doses, discuss a routine or alternative treatment that may be easier to manage.
A tablet can be a useful option if you prefer to avoid injections and can follow the empty-stomach routine. A weekly injection may fit better if daily dosing is difficult. We also consider what each medicine is registered to treat, its evidence and your medical history.
|
Treatment and Active Ingredient |
Frequency |
Main Registered Uses in Adults |
Practical Consideration |
|---|---|---|---|
|
Novo Nordisk’s oral semaglutide, 3 mg, 7 mg or 14 mg |
Daily tablet |
Type 2 diabetes |
No injection; requires an empty stomach and a waiting period before food, drinks and other oral medicines |
|
Novo Nordisk’s semaglutide diabetes injection |
Weekly |
Type 2 diabetes |
Weekly dosing; prescribing solely for weight loss is off-label |
|
Novo Nordisk’s semaglutide weight-management injection, including 2.4 mg |
Weekly |
Weight management in eligible patients |
Different prescribing schedule from the diabetes injection; treatment begins at a lower dose |
|
Eli Lilly’s tirzepatide injection, Singapore-registered four-dose pen |
Weekly |
Type 2 diabetes and weight management under the respective prescribing conditions |
Acts on both GIP and GLP-1 receptors; the dose is increased gradually when appropriate |
This table summarises the main uses relevant to this discussion, rather than every prescribing condition. These medicines are alternatives to assess with your doctor, not treatments to combine on your own. Oral and injectable doses cannot be compared milligram for milligram, so switching requires a plan for when to stop one medicine and begin the next.
For an overview of the weekly options, visit https://edwinlimclinic.sg/weight-loss-injections-singapore-guide/
If your main question is how the tablet differs from Novo Nordisk’s weekly semaglutide diabetes injection, the dedicated guide explains that treatment at https://edwinlimclinic.sg/ozempic-singapore/
For a semaglutide formulation intended for weight management, read about Novo Nordisk’s once-weekly treatment and its established 2.4 mg trial dose at https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
To understand how a dual GIP/GLP-1 medicine differs, explore Eli Lilly’s weekly tirzepatide treatment at https://edwinlimclinic.sg/mounjaro-tirzepatide-injection-for-weight-loss-in-singapore-doctors-comprehensive-guide/
There are different oral GLP-1 treatments and formulations. If you have read about a newer tablet, check its active ingredient and intended use. Approval in another country does not by itself establish registration or availability in Singapore.
This refers to a separate weight-management formulation, rather than the 3 mg, 7 mg and 14 mg diabetes tablets covered here. Read about its evidence and status in the dedicated guide at https://edwinlimclinic.sg/oral-wegovy-pill-weight-loss-singapore/
Orforglipron is a different active ingredient from semaglutide. If you are comparing oral options, its studies, prescribing requirements and local status need to be considered separately. Learn more at https://edwinlimclinic.sg/orforglipron-singapore/
Nausea, vomiting, diarrhoea, constipation and abdominal discomfort can occur, particularly when starting treatment or increasing the dose. Mild symptoms may settle, but you should let us know if they persist or affect your ability to eat, drink or carry out your usual activities.
Smaller meals and avoiding foods that worsen nausea may help. Keep fluids up once the post-tablet waiting period has passed. We can review your symptoms and prescription if the current plan is difficult to tolerate.
Severe or persistent abdominal pain, especially with vomiting, needs urgent assessment because pancreatitis and other abdominal conditions must be considered. Repeated vomiting, inability to keep fluids down or markedly reduced urination also needs prompt care. Seek emergency help for breathing difficulty, collapse or swelling of the face or throat.
The European Medicines Agency has identified non-arteritic anterior ischaemic optic neuropathy (NAION) as a very rare side effect of semaglutide, including the oral formulation. This condition affects the optic nerve and can cause loss of vision. This is an international safety assessment, not a Singapore-specific estimate of risk.
Sudden loss of vision, partial visual loss or rapidly worsening eyesight requires urgent medical assessment. If NAION is confirmed, semaglutide should be stopped. Diabetes-related retinopathy is a separate eye condition; tell your doctor if you have it so that monitoring can be considered as blood sugar improves.
Bring a complete medication list, including supplements. Insulin or sulfonylureas can increase the risk of low blood sugar when used with semaglutide. Levothyroxine may require additional thyroid monitoring, and patients taking warfarin may need closer INR monitoring when treatment begins.
Tell your anaesthetist or procedural team that you take semaglutide before surgery or sedation. They will advise on preparation and whether treatment needs to be adjusted. Do not add another GLP-1 medicine or a dual GIP/GLP-1 treatment without discussing your existing prescription with the doctor.
If your appetite is smaller, aim to make the meals you do eat nourishing. Include a protein source such as fish, eggs, lean meat, tofu or dairy, together with vegetables and other foods that provide a balanced diet. At a hawker centre, this might mean choosing a meal with protein and vegetables and adjusting the rice or noodle portion to your needs.
Resistance exercise, adapted to your health and ability, helps support muscle preservation during weight loss. Walking and other regular activity can complement this. If you have kidney disease or need a specialised diet, ask for individual advice rather than following a generic high-protein plan.
Let us know if reduced appetite is turning into difficulty eating enough. The aim is a manageable treatment plan that supports your health over time.
Appetite may increase after treatment stops, and weight regain is possible. Research on withdrawal of injectable semaglutide supports planning for this stage, but its exact regain percentages should not be applied to the lower-dose oral tablets.
Before stopping, we discuss how you will manage meals, activity and weight monitoring, and when to return for review. If your weight begins rising consistently, a review can help identify what needs to change. Regain is a reason to reassess the plan, rather than a reason to blame yourself.
If the medicine is also treating diabetes, stopping can affect blood sugar control. Coordinate changes with the doctor managing your diabetes. Gradual dose reduction has not been established as a reliable way to prevent weight regain.
Oral semaglutide medication starts from S$308 before GST for a month’s supply. Prices depend on the prescribed dose. The initial in-person consultation is S$60 before GST, and follow-up consultations are also S$60 before GST per consultation, charged separately from medication.
At the first appointment, bring details of any previous weight-management treatment, including the dose, when you last took it and any side effects. This helps us advise you on starting or changing treatment. Blood tests are requested when clinically indicated rather than routinely for every patient; ongoing diabetes monitoring remains important where relevant.
Before you leave, we explain how to take the tablet and when to review progress. At follow-up, we discuss your appetite, weight trend and side effects, and review measures such as blood pressure and blood sugar where appropriate. You can WhatsApp the clinic with questions between visits. If you develop urgent symptoms, seek medical care promptly rather than waiting for a message reply.
Learn more about our personalised medical weight loss programme at https://edwinlimclinic.sg/personalised-medical-weight-loss-program-in-singapore/
Consultations are available at Changi City Point, 5 Changi Business Park Central 1, #02-12/13, Singapore 486038, and at Lucky Plaza, 304 Orchard Road, #05-51, Singapore 238863. Orchard consultations are by appointment.
Call +65 6904 2218 or send a WhatsApp message to +65 9637 2218 at https://wa.me/6596372218
View clinic contact information at https://edwinlimclinic.sg/contact-number/
Read about Dr Edwin Lim’s background at https://edwinlimclinic.sg/about-overview/
Dr Edwin Lim
MBBS (Singapore), MRCS (Edinburgh), PgDip Practical Dermatology (Cardiff), MSc Practical Dermatology (Cardiff), Diploma in Aesthetic Medicine, (AAAM), Accredited by the Aesthetic Dermatology Educational Group (ADEG)
